South Korea’s biopharmaceutical powerhouse Celltrion said on March 11 that its U.S. affiliate had submitted a biologics license application for CT-P39 to the U.S. Food and Drug Administration.CT-P39 refers to an interchangeable biosimilar candidate to XOLAIR (omalizumab), an injectable biologic medi
South Korea’s biopharmaceutical behemoth Celltrion announced on March 5 that the company would spend some 75 billion won ($56 million) to buy back its shares.With the funds, the company plans to buy more than 420,000 shares on March 6 on the country’s main bourse in a move to boost its share price.T
South Korean biopharmaceutical powerhouse Celltrion announced on Feb. 28 that it had shipped the first batch of its new autoimmune disease treatment Zymfentra to the United States.The treatment, otherwise known as Remsima SC, is set to debut in the United States next month.As a subcutaneous injectio
South Korea’s leading biopharmaceutical company Celltrion said on Jan. 29 that it had submitted a biologics license application to the U.S. Food and Drug Administration (FDA) for Celltrion, a biosimilar candidate of the reference product Celltrion.The submission was based on data from the global Pha
South Korea’s top-tier biopharmaceutical company Celltrion announced its ambition to become an innovative company focused on new drug development on Jan. 10.The developer of the world’s first monoclonal antibody biosimilar disclosed the strategic goal during the 42nd edition of the Annual J.P. Morga
South Korea’s biopharmaceutical giant Celltrion announced on Jan. 8 that the company would cancel around 1 percent of its outstanding shares worth about 500 billion won ($380 million).Specifically, the Incheon-based firm is scheduled to cancel some 2.3 million shares, or 1.05 percent, next week to r
A Humira biosimilar added to Carepartners Specialty Pharmacy ProgramSouth Korean pharmaceutical giant Celltrion announced on Oct. 26 that its FDA-approved biosimilar Yuflyma had been added to CarePartners Specialty Pharmacy Cost Savings Programs in the United States.As a result, CarePartners and its
Strong demand for biosimilar products boost Celltrion performancesSouth Korea’s leading pharmaceutical company Celltrion announced on Oct. 24 that its third-quarter net income had rocketed 32.6 percent from a year before.The company said that strong demand for its biosimilar products in the world ma
Two medical giants to form a single entityCelltrion Group said on Oct. 23 that its two affiliates of Celltion and Celltrion Healthcare would be merged after winning the approval of shareholders of the two outfits.Earlier this August, Celltrion Group announced that the two medical giants would become
Korean pharmaceutical firm achieves exploitSouth Korea’s pharmaceutical company Celltrion said Monday that its anti-inflammatory medicine had won the approval of the U.S. Food and Drug Administration.The treatment, dubbed Zymfentra, is targeted for maintenance therapy in adults with moderately to se
Ventegra will incorporate Yuflyma as a preferred drugCelltrion announced on Oct. 5 that the South Korean pharmaceutical giant had signed a contract with Ventegra, a U.S. medical benefit manager administering pharmacy benefits.Under the agreement, Ventegra will incorporate Yuflyma as a preferred drug
Yuflyma strives to tap into the U.S. marketSouth Korean pharmaceutical company Celltrion said on May 25 that its Humira biosimilar CT-P17, or Yuflyma, had won the approval of the U.S. Food and Drug Administration (FDA).Beginning in July, Celltrion plans to sell Yuflyma, a high-concentration and citr
Korean firm will supply rapid COVID-19 test kit in contract worth $626 millionSouth Korea’s leading biopharmaceutical company Celltrion recently said that it had secured a mega-sized contract to supply rapid COVID-19 test kits to the United States military.Under the deal, Celltrion USA will deliver
South Korea gives nod to antibody treatmentCelltrion said this week that the Korean Ministry of Food and Drug Safety (MFDS) approved its monoclonal antibody treatment for the novel coronavirus, named regdanvimab (CT-P59).Following the measure, the treatment commercially known as Regkirona will be ex
Korean pharmaceutical firm joins competition to market pandemic treatmentSouth Korea’s pharmaceutical company Celltrion announced on June 14 that its COVD-19 treatment, called Rekirona, was safe and efficient in dealing with the virus pandemic at its phase-three clinical tests.The company located in
Celltrion’s treatment candidate reduces recovery time by up to 6 daysCelltrion said this week that its treatment for the novel coronavirus would be available in late January at the earliest as top-line results of its trial test shows positive results.The Incheon-based company announced the phase II
Korean biosimilar maker promises to invest $34 billionCelltrion, a Korean biosimiar manufacturer, strives to surpass U.S. juggernaut Pfizer by 2030, according to the former’s Chairman Seo Jung-jin on May 16.Toward that end, Seo said that the Incheon-based company will invest 40 trillion won ($34 bil
As of May 13 11:55 A.M., Celltrion declined 2.48 percent, compared with yesterday, to 196,500 won. It had declined 4.38 percent through the past month. Compared with its close competitors within the same industry, KOSPI, even though the investment return of Celltrion was the most satisfactory among
Korean outfit gains U.S. approvalA company with annual sales of around $1 billion can double in size every year? Most investors would be skeptical, but that’s what one of Korea’s biggest firms Celltrion tries to do.During the shareholders’ meeting earlier this year, Celltrion Chairman Seo Jung-jin s
As of Apr. 8 01:55 P.M., Celltrion increased 1.56 percent, compared with yesterday, to 195,000 won. It had declined 5.34 percent through the past month.Compared with its close competitors within the same industry, KOSPI, even though the investment return of Celltrion was satisfactory among its peer